Hong Kong is calling for robotaxi operator Pony AI . The $6 billion Chinese company is exploring an offering in the city just ...

City’s largest share sale in four years shows Beijing’s determination to push China’s EV technologies worldwide, analysts say ...

Trading in the shares is expected to start on May 23. Read more at straitstimes.com. Read more at straitstimes.com.

Jiangsu Hengrui Pharmaceuticals is planning to raise as much as US$1.27 billion via an initial public offering in Hong Kong, joining a wave of Chinese companies seeking to tap the city's market.

Singapore-based medical testing firm Mirxes joins Jiangsu Hengrui Pharmaceuticals in revitalised market’s listing surge.

The underwriters on Hengrui Pharmaceutical Hong Kong listing are represented by Herbert Smith Freehills and Jingtian & ...

SINGAPORE] Singapore biotech start-up Mirxes launched its initial public offering (IPO) in Hong Kong on Thursday (May 15) as ...

Now, with tensions easing and the US$43.6 billion ($56.62 billion) raised in 2025 IPOs so far running just behind the same ...

(Reuters) -Chinese drug developer and producer Jiangsu Hengrui Pharmaceuticals is seeking to raise up to HK$9.89 billion ($1.27 billion) in a Hong Kong initial public offering, according to a ...

Chinese drug developer and producer Jiangsu Hengrui Pharmaceuticals is seeking to raise up to HK$9.89 billion ($1.27 billion) in a Hong Kong listing, according to a regulatory filing made on Thursday.

And another scoop: Two of FTI Consulting’s top economics experts in Europe have left to join Jonathan Orszag’s upstart rival ...